EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

A Lineup for Next Anti-Obesity Medicines: Beyond Incretin-Based Pharmacotherapy

Sangmin Lee iD, Hyeseon Song, Yeonwoo Kwon

Pharmaceuticals · 07.07.2026 · 19 (7) · 1047

DOI: 10.3390/ph19071047 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 07.07.2026. Verfasst von Sangmin Lee und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Sciences, Graduate School, Dong-A University, Busan 49315, Republic of Korea. Die Arbeit nennt 211 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Busan TechnoPark, Ministry of Education, Dong-A University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Obesity is a chronic and multifactorial disease, and the global prevalence of obesity-induced metabolic and systemic complications is expected to rise. Current peptide-based drugs that mainly target glucagon-like peptide-1 receptor activation have shown unprecedented efficacy in body weight reduction. Nevertheless, they show undesirable adverse effects including gastrointestinal effects, lean mass reduction, and rebound weight gain after ending pharmacotherapy. These underscore the medical need for additional anti-obesity drugs with novel pathways.

Methods

Literature updating current anti-obesity pharmacotherapy and reporting potential drug targets and candidates in the last five years was searched across PubMed. The resulting literature was classified into working mechanisms and target receptors.

Results

Recent research on incretin-based peptide drugs has focused on developing more convenient regimens by introducing longer-acting once-monthly injection or oral formulation. Novel anti-obesity targets other than incretin receptors have also been suggested. This narrative review summarizes recent research updates on peptide-based drugs and upcoming anti-obesity drug candidates tested in clinical and in vivo studies.

Conclusions

Beyond the current peptide-based pharmacotherapy, novel anti-obesity drug candidates are waiting for further validation in clinical trials. When used alone or combined with the available drugs, these candidates may produce more effective and safer pharmacotherapy for obesity treatment.

Schlagwörter

Stichwörter der Autor:innen

incretin-based drugsnovel drug targetsobesity

Autor:innen und Institutionen

  • Department of Health Sciences, Graduate School, Dong-A University, Busan 49315, Republic of Korea.
  • Department of Medicinal Biotechnology, College of Health Science, Dong-A University, Busan 49315, Republic of Korea.

ORCID-Profile: Sangmin Lee

Förderung

  • Busan TechnoPark
  • Ministry of Education
  • Dong-A University
  • Busan Metropolitan City
  • Busan Techno Park
  • BB21plus

Zitieren

APA

Lee, S., Song, H., & Kwon, Y. (2026). A Lineup for Next Anti-Obesity Medicines: Beyond Incretin-Based Pharmacotherapy. Pharmaceuticals, 19(7), 1047. https://doi.org/10.3390/ph19071047

Vancouver

Lee S, Song H, Kwon Y. A Lineup for Next Anti-Obesity Medicines: Beyond Incretin-Based Pharmacotherapy. Pharmaceuticals. 2026;19(7):1047. doi:10.3390/ph19071047

BibTeX
@article{Lee2026,
  author = {Lee, Sangmin and Song, Hyeseon and Kwon, Yeonwoo},
  title = {A Lineup for Next Anti-Obesity Medicines: Beyond Incretin-Based Pharmacotherapy},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {7},
  pages = {1047},
  doi = {10.3390/ph19071047}
}
Kostenlos starten →